Oncoscope Inc, spun off from Southeast TechInventures, Inc. and from research done at Duke Universitys Department of Biomedical Engineering, develops diagnostic systems that use proprietary optical technologies to locate pre-cancerous cells in epithelial tissues where 85% of all cancers begin. The technology, known as Angle-resolved low-coherence interferometry (a/LCI) uses the properties of scattered light in order to measure the average size of cell structures, including the cell nuclei. Oncoscope has developed an Optical Biopsy System that uses a/LCI technology to offer realtime, invivo identification of dysplastic tissue and guide sample selection, improving diagnostic accuracy while also eliminating the frustration and excessive cost associated with random biopsy. These devices are fast, accurate, non-invasive, and allow the examination of large tissue areas. Most importantly, Oncoscopes technology detects early pre-cancerous dysplasia, a breakthrough over existing diagnostic methods. A recent clinical study showed that Oncoscopes system was accurately able to detect precancerous tissue 97% of the time. In 2015, Oncoscope filed for bankruptcy with, soon after, SpectraScience Inc acquiring all the assets of the firm.
